Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice

Heidi D. Finnes, PharmD, Kari G. Chaffee, MS, Timothy G. Call, MD, Wei Ding, MD PhD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Kristen B. McCullough, PharmD, Julianna A. Merten, PharmD, Gabriel T. Bartoo, PharmD, Matthew D. Smith, PharmD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2015) 126 (23): 717.

https://doi.org/10.1182/blood.V126.23.717.717

Published: 2015

Journal Articles

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Oliver Weigert, MD, Andrew A. Lane, MD, PhD, Liat Bird, Nadja Kopp, Angela V Toms, Ph.D., Christoph Gaul, Eric Vangrevelinghe, Alain De Pover, Catherine H. Regnier, PhD, Dirk Erdmann, Francesco Hofmann, PhD, Michael Eck, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 62.

https://doi.org/10.1182/blood.V118.21.62.62

Published: 2011

Journal Articles

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

Swaminathan Padmanabhan, MBBS, MD, Kevin R Kelly, MD, Mark Heaney, MD, PhD, Stephanie Hodges, Suzanne Chanel, RN, Mark Frattini, MD, Ronan Swords, MD, MRCPI, FRCPath, Robert Bradley, Florentina Teofilovici, MD, MS, Daniel J DeAngelo, MD, PhD

Blood (2010) 116 (21): 2898.

https://doi.org/10.1182/blood.V116.21.2898.2898

Published: 2010

Journal Articles

Preclinical Evaluation of A Potent 2 nd Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines

Weiwen Ying, David Proia, Suqin He, Jim Sang, Kevin Foley, Zhenjian Du, Ronald k Blackman, Yumiko Wada, Lijun Sun, Keizo Koya

Blood (2010) 116 (21): 2899.

https://doi.org/10.1182/blood.V116.21.2899.2899

Published: 2010

Journal Articles

A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies

Jeffrey E. Lancet, MD, B. Douglas Smith, MD, Robert Bradley, Rami S. Komrokji, MD, Florentina Teofilovici, MD, David A. Rizzieri, MD

Blood (2010) 116 (21): 3294.

https://doi.org/10.1182/blood.V116.21.3294.3294

Published: 2010

Journal Articles

The Safety, Pharmacokinetics and Pharmacodynamics of KW-2478, a Novel Hsp90 Antagonist, in Patients with B-Cell Malignancies: A First-in-Man, Phase I, Multicentre, Open-Label, Dose Escalation Study

J. D. Cavenagh, MD, MRCP, K. Yong, J. Byrne, J. Cavet, P. Johnson, G. Morgan, C. Williams, S. Akinaga, G. Francis, J. Kilborn

Blood (2008) 112 (11): 2777.

https://doi.org/10.1182/blood.V112.11.2777.2777

Published: 2008

Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel

Blood (2008) 112 (11): 1625.

https://doi.org/10.1182/blood.V112.11.1625.1625

Published: 2008

Journal Articles

Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.

Douglas W. McMillin, Joseph Negri, Jake Delmore, Patrick Hayden, Melissa Ooi, Nicholas Mitsiades, Robert Schlossman, Paul G. Richardson, Nikhil C. Munshi, Michael R. Jensen, Cornelia Quadt, Patrick Chène, Joseph Schoepfer, Carlos García-Echeverría, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2007) 110 (11): 1587.

https://doi.org/10.1182/blood.V110.11.1587.1587

Published: 2007

Journal Articles

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

Gael Roue, PhD, Patricia Perez-Galan, PhD, Monica Lopez-Guerra, BS, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD

Blood (2007) 110 (11): 1601.

https://doi.org/10.1182/blood.V110.11.1601.1601

Published: 2007

Journal Articles

Additive Interaction between Oxaliplatin and DMAG in Pediatric Acute Lymphoblastic Leukemia (ALL) Cells. Evidence for Interference with Multiple Signaling Pathways.

Aarthy Jayanthan, Jane Fowler, Lucas Coppes, Tanya Trippett, Ron Anderson, Aru Narendran

Blood (2005) 106 (11): 4590.

https://doi.org/10.1182/blood.V106.11.4590.4590

Published: 2005

Journal Articles

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Sundar Jagannath, MD, David Siegel, MD, Paul Richardson, MD, Amitabha Mazumder, MD, Jens Sydor, PhD, Jill Goddard, John Walker, Jon Patterson, Emmanuel Normant, PhD, Jeffrey Tong, PhD, Vito Palombella, PhD, Ken Anderson, MD, Julian Adams, PhD, David Grayzel, MD

Blood (2005) 106 (11): 2560.

https://doi.org/10.1182/blood.V106.11.2560.2560

Published: 2005

Journal Articles

Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.

James Bradner, MD, John Paul Shen, BS, Edward Greenberg, BS, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD, Stuart L. Schreiber, PhD

Blood (2005) 106 (11): 2471.

https://doi.org/10.1182/blood.V106.11.2471.2471

Published: 2005

Journal Articles

Quantitative Analysis of Protein Expression Changes Induced by Geldanamycin in NPM-ALK Positive Lymphoma Cells by Functional Proteomics.

Jonathan A. Schumacher, David K. Crockett, Zhaoshang Lin, Ph.D., Kojo S.J. Elenitoba-Johnson, M.D., Megan S. Lim, M.D. Ph.D.

Blood (2004) 104 (11): 2278.

https://doi.org/10.1182/blood.V104.11.2278.2278

Published: 2004

Journal Articles

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Joseph Negri, Corey C. Geer, MSc, Melissa Pink, Christine Pien, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Paul G. Richardson, MD, John Barrett, PhD, Jeffrey K. Tong, PhD, David Grayzel, Vito Palombella, PhD, Julian Adams, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2403.

https://doi.org/10.1182/blood.V104.11.2403.2403

Published: 2004

Journal Articles

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Robert Johnson, MD, Alison Hannah, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2404.

https://doi.org/10.1182/blood.V104.11.2404.2404

Published: 2004

Journal Articles

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

Gerard Fumo, Cem Akin, Dean D. Metcalfe, Len Neckers

Blood (2004) 103 (3): 1078–1084.

https://doi.org/10.1182/blood-2003-07-2477

Published: 2004

Journal Articles

Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth

M Okabe, Y Uehara, T Miyagishima, T Itaya, M Tanaka, Y Kuni-Eda, M Kurosawa, T Miyazaki

Blood (1992) 80 (5): 1330–1338.

https://doi.org/10.1182/blood.V80.5.1330.1330

Published: 1992

NARROW

The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

Preclinical Evaluation of A Potent 2 nd Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines

A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies

The Safety, Pharmacokinetics and Pharmacodynamics of KW-2478, a Novel Hsp90 Antagonist, in Patients with B-Cell Malignancies: A First-in-Man, Phase I, Multicentre, Open-Label, Dose Escalation Study

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

Additive Interaction between Oxaliplatin and DMAG in Pediatric Acute Lymphoblastic Leukemia (ALL) Cells. Evidence for Interference with Multiple Signaling Pathways.

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.

Quantitative Analysis of Protein Expression Changes Induced by Geldanamycin in NPM-ALK Positive Lymphoma Cells by Functional Proteomics.

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only